Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

AGB101 for Preclinical Alzheimer's Disease

Start: April 11, 2019
End: May 31, 2021
Enrollment: 26

What Is This Study About?

AGB101 is an extended-release, low-dose preparation of levetiracetam, a drug approved by the U.S. Food and Drug Administration to treat certain types of seizures. It works by decreasing abnormal excitement in the brain. In this study researchers are investigating whether the drug can reduce abnormal brain activity and improve memory. Participants will be randomly assigned to take a capsule of the study drug or a placebo once daily for two weeks. After a four-week washout period (i.e., not taking the study drug or placebo), participants will rotate groups and take either the study drug or a placebo for another two weeks.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 75 Years

Must have:

  • Fluent in English
  • At least eight years of education
  • Geriatric Depression Scale score less than 6
  • Hachinski Ischemic Score of 4 or less
  • Normal general cognitive function and normal memory function, as determined by cognitive assessments

Must NOT have:

  • Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis
  • History of significant head trauma or known structural brain abnormalities
  • Major psychiatric disease or chronic unstable medical conditions
  • History of drug abuse
  • History of alcohol abuse (four or more drinks per day on average)
  • Unable to complete magnetic resonance imaging scans (e.g., pacemaker/defibrillator)
  • Significant abnormalities in B12 or thyroid function tests
  • End-stage renal disease
  • Dialysis

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Shelby Schold
Barbara Blaney

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Medical College of Wisconsin

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ID: NCT03461861

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health